Down‐regulation of RCC1 sensitizes immunotherapy by up‐regulating PD‐L1 via p27(kip1)/CDK4 axis in non‐small cell lung cancer

In recent years, although Immune Checkpoint Inhibitors (ICIs) significantly improves survival both in local advanced stage and advanced stage of non‐small cell lung cancer (NSCLC), the objective response rate of ICI monotherapy is still only about 20%. Thus, to identify the mechanisms of ICI resista...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xiaozhu, Zhong, Maoxi, Yang, Yumeng, Wang, Zhi, Zhu, Yuxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051708/
https://www.ncbi.nlm.nih.gov/pubmed/33630417
http://dx.doi.org/10.1111/jcmm.16383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051708/
https://www.ncbi.nlm.nih.gov/pubmed/33630417
http://dx.doi.org/10.1111/jcmm.16383

Ejemplares similares